Business Context and Reporting Period
This Form 8-K is a current report filed by Silverback Therapeutics, Inc. (not ARS Pharmaceuticals, Inc.) on March 11, 2022. The registrant is a Delaware corporation with principal executive offices in Seattle, Washington, and its common stock trades on The Nasdaq Stock Market under the symbol SBTX. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director:
- Thilo Schroeder, Ph.D. informed the Company on March 11, 2022, that he will not stand for re-election as a Class II director at the 2022 annual meeting of stockholders.
- On March 14, 2022, Dr. Schroeder resigned from the Audit Committee to focus on other endeavors.
- The Company stated that neither the decision not to stand for re-election nor the resignation resulted from any dispute or disagreement regarding the Company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the disclosure of the director's departure.
Investor Verification Checklist
- Verify the composition of the Board of Directors following Dr. Schroeder's departure.
- Confirm the status of the Audit Committee and whether a replacement member has been appointed.
- Review the Company's upcoming 2022 annual meeting proxy statement for details on director nominations.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.